<?xml version="1.0" encoding="UTF-8"?>
<p id="p0020">As we know, opioids depress respiratory drive
 <xref rid="bib7" ref-type="bibr">
  <sup>7</sup>
 </xref> and long-term use is immunosuppressive,
 <xref rid="bib8" ref-type="bibr">
  <sup>8</sup>
 </xref> although direct clinical trial evidence for the latter is lacking.
 <xref rid="bib9" ref-type="bibr">
  <sup>9</sup>
 </xref> That said, some of the seminal early work showing opioid immunosuppression is based on data showing increased infections in addicts.
 <xref rid="bib10" ref-type="bibr">
  <sup>10</sup>
 </xref> COVID infection is more likely to produce adverse outcomes in immunosuppressed patients, and this is part of the scientific evidence for shielding in this patient group. The respiratory effects of COVID-19 infection are known only too well to anaesthetists and intensivists, and ventilation of acutely unwell patients has been the mainstay of treatment and of ICU workload. Opioids may be required for pain management in COVID-19 patients,
 <xref rid="bib11" ref-type="bibr">
  <sup>11</sup>
 </xref> and paradoxically opioids have been suggested in COVID-19 palliative care for patients experiencing the sensation of suffocation.
 <xref rid="bib12" ref-type="bibr">
  <sup>12</sup>
 </xref>
</p>
